Novavax, Inc (NASDAQ: NVAX) on Friday, plunged -1.69% from the previous trading day, before settling in for the closing price of $8.27. Within the past 52 weeks, NVAX’s price has moved between $3.60 and $23.86.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 653.01% over the last five years. The company achieved an average annual earnings per share of 76.43%. With a float of $152.86 million, this company’s outstanding shares have now reached $160.15 million.
The firm has a total of 1543 workers. Let’s measure their productivity. In terms of profitability, gross margin is 66.75%, operating margin of -33.36%, and the pretax margin is -31.6%.
Novavax, Inc (NVAX) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Novavax, Inc is 4.52%, while institutional ownership is 60.41%. The most recent insider transaction that took place on Dec 13 ’24, was worth 37,435. In this transaction Director of this company sold 4,150 shares at a rate of $9.02, taking the stock ownership to the 14,770 shares. Before that another transaction happened on Dec 31 ’24, when Company’s Director sold 5,400 for $8.00, making the entire transaction worth $43,200. This insider now owns 51,760 shares in total.
Novavax, Inc (NVAX) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 76.43% per share during the next fiscal year.
Novavax, Inc (NASDAQ: NVAX) Trading Performance Indicators
Novavax, Inc (NVAX) is currently performing well based on its current performance indicators. A quick ratio of 0.93 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.47.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.26, a number that is poised to hit -0.66 in the next quarter and is forecasted to reach 0.12 in one year’s time.
Technical Analysis of Novavax, Inc (NVAX)
Analysing the last 5-days average volume posted by the [Novavax, Inc, NVAX], we can find that recorded value of 3.17 million was lower than the volume posted last year of 4.62 million. As of the previous 9 days, the stock’s Stochastic %D was 12.74%. Additionally, its Average True Range was 0.58.
During the past 100 days, Novavax, Inc’s (NVAX) raw stochastic average was set at 15.70%, which indicates a significant increase from 3.47% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 61.59% in the past 14 days, which was lower than the 78.05% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $8.80, while its 200-day Moving Average is $11.16. Now, the first resistance to watch is $8.31. This is followed by the second major resistance level at $8.49. The third major resistance level sits at $8.61. If the price goes on to break the first support level at $8.01, it is likely to go to the next support level at $7.89. Should the price break the second support level, the third support level stands at $7.71.
Novavax, Inc (NASDAQ: NVAX) Key Stats
Market capitalization of the company is 1.30 billion based on 160,185K outstanding shares. Right now, sales total 983,710 K and income totals -545,060 K. The company made 84,510 K in profit during its latest quarter, and -121,300 K in sales during its previous quarter.
